AMRN
Amarin Corporation plc NASDAQ Listed Apr 1, 1993$14.84
Mkt Cap $306.9M
52w Low $9.98
44.5% of range
52w High $20.90
50d MA $14.63
200d MA $15.48
P/E (TTM)
-156.3x
EV/EBITDA
-136.5x
P/B
12.7x
Debt/Equity
0.0x
ROE
-7.5%
P/FCF
859.0x
RSI (14)
—
ATR (14)
—
Beta
0.82
50d MA
$14.63
200d MA
$15.48
Avg Volume
73.3K
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Grand Canal Docklands · Dublin 2 · IE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | BMO | 0.01 | -0.09 | -1000.0% | 13.96 | -0.4% | +2.4% | -0.2% | +0.8% | +2.0% | +3.9% | — |
| Feb 25, 2026 | BMO | 0.07 | 0.01 | -85.7% | 15.52 | -1.0% | -9.5% | -9.0% | -11.1% | -10.2% | -7.5% | — |
| Oct 29, 2025 | BMO | 0.08 | 0.01 | -87.5% | 18.94 | -2.3% | -11.2% | -13.4% | -14.0% | -17.3% | -19.7% | — |
| Jul 30, 2025 | BMO | -0.66 | -0.03 | +95.5% | 14.65 | +2.3% | +2.2% | -0.9% | +3.5% | +5.0% | +3.3% | — |
| May 7, 2025 | BMO | -1.12 | -0.04 | +96.4% | 10.19 | -1.9% | -0.1% | +5.1% | +2.2% | +2.3% | +0.8% | — |
| Mar 12, 2025 | BMO | -1.20 | -2.40 | -100.0% | 9.41 | -13.9% | -15.0% | -12.9% | -12.0% | -11.8% | -8.1% | — |
| Oct 30, 2024 | BMO | -1.00 | -1.00 | +0.0% | 12.24 | +6.2% | -1.6% | -5.3% | -4.2% | -1.2% | +1.8% | — |
| Jul 31, 2024 | BMO | 0.10 | 0.20 | +100.0% | 15.65 | +0.5% | -12.8% | -20.6% | -18.2% | -16.4% | -9.8% | — |
| May 1, 2024 | BMO | -0.80 | -0.20 | +75.0% | 18.42 | -7.7% | -8.8% | -0.3% | -1.2% | +6.4% | +5.9% | — |
| Feb 29, 2024 | BMO | -0.01 | -0.01 | -66.7% | 26.40 | -10.6% | -18.9% | -19.7% | -30.0% | -28.7% | -28.1% | — |
| Nov 1, 2023 | BMO | -0.04 | -0.05 | -11.1% | 13.92 | +0.6% | +0.3% | -5.2% | +4.6% | +11.4% | +12.1% | — |
| Aug 2, 2023 | BMO | -0.40 | 0.40 | +200.0% | 23.80 | -2.5% | +0.0% | +0.0% | -0.8% | -3.4% | -1.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 25 | Goldman Sachs | Maintains | Sell → Sell | — | $16.04 | $16.19 | +0.9% | +0.9% | -0.9% | -2.1% | +1.1% | +4.8% |
| Apr 17 | Goldman Sachs | Maintains | Sell → Sell | — | $9.36 | $9.01 | -3.7% | -2.7% | +2.0% | +11.8% | +10.7% | +19.4% |
| Oct 25 | Jefferies | Downgrade | Buy → Hold | — | $15.21 | $14.94 | -1.8% | -6.1% | -8.8% | -9.3% | -9.9% | -8.5% |
| Jul 20 | Goldman Sachs | Maintains | Sell → Sell | — | $21.60 | $22.20 | +2.8% | +3.7% | +3.7% | +7.4% | +4.6% | +5.6% |
| Jul 19 | Northland Capital Markets | Maintains | Market Perform → Market Perform | — | $28.60 | $22.80 | -20.3% | -24.5% | -21.7% | -21.7% | -18.9% | -21.0% |
| Jan 6 | Jefferies | Upgrade | Hold → Buy | — | $25.20 | $26.60 | +5.6% | +14.3% | +17.5% | +36.5% | +44.4% | +54.8% |
| Oct 19 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $23.40 | $23.00 | -1.7% | -8.5% | -6.8% | -4.3% | -5.1% | -1.7% |
| May 24 | Goldman Sachs | Maintains | Sell → Sell | — | $28.20 | $28.00 | -0.7% | -7.1% | -3.5% | +1.4% | +2.1% | +2.8% |
| May 6 | JP Morgan | Downgrade | Neutral → Underweight | — | $27.00 | $26.40 | -2.2% | -0.7% | -5.9% | -6.7% | -16.3% | -7.4% |
| May 5 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $31.20 | $29.40 | -5.8% | -13.5% | -14.1% | -18.6% | -19.2% | -27.6% |
| May 5 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $31.20 | $29.40 | -5.8% | -13.5% | -14.1% | -18.6% | -19.2% | -27.6% |
| Feb 16 | SVB Leerink | Maintains | Outperform → Outperform | — | $71.60 | $70.40 | -1.7% | -3.1% | -6.4% | -7.5% | -10.6% | -12.6% |
| Jan 31 | SVB Leerink | Maintains | Outperform → Outperform | — | $67.20 | $68.60 | +2.1% | +7.7% | +11.0% | +7.1% | +8.3% | +8.9% |
| May 12 | Goldman Sachs | Downgrade | Neutral → Sell | — | $92.20 | $88.00 | -4.6% | -5.6% | -7.6% | -5.0% | -6.3% | -1.5% |
| Feb 1 | SVB Leerink | Maintains | Outperform → Outperform | — | $150.00 | $160.20 | +6.8% | +7.7% | +9.3% | +17.3% | +14.7% | +12.3% |
| Sep 28 | SVB Leerink | Maintains | Outperform → Outperform | — | $76.20 | $80.00 | +5.0% | +5.0% | +6.0% | +10.5% | +11.8% | +17.3% |
| May 4 | Aegis Capital | Maintains | Buy → Buy | — | $146.80 | $142.00 | -3.3% | +3.8% | +5.2% | +0.7% | +2.5% | +5.0% |
| May 4 | SVB Leerink | Maintains | Outperform → Outperform | — | $146.80 | $142.00 | -3.3% | +3.8% | +5.2% | +0.7% | +2.5% | +5.0% |
| Apr 1 | Citigroup | Maintains | Buy → Buy | — | $80.00 | $80.40 | +0.5% | +24.5% | +30.5% | +19.5% | +20.0% | +26.0% |
| Mar 31 | Oppenheimer | Upgrade | Underperform → Perform | — | $271.60 | $83.80 | -69.1% | -70.5% | -63.3% | -61.6% | -64.8% | -64.7% |
| Mar 31 | Goldman Sachs | Downgrade | Buy → Neutral | — | $271.60 | $83.80 | -69.1% | -70.5% | -63.3% | -61.6% | -64.8% | -64.7% |
| Mar 31 | Jefferies | Downgrade | Buy → Hold | — | $271.60 | $83.80 | -69.1% | -70.5% | -63.3% | -61.6% | -64.8% | -64.7% |
| Mar 31 | Stifel | Maintains | Hold → Hold | — | $271.60 | $83.80 | -69.1% | -70.5% | -63.3% | -61.6% | -64.8% | -64.7% |
| Mar 13 | Goldman Sachs | Upgrade | Neutral → Buy | — | $230.00 | $263.60 | +14.6% | +9.1% | -10.8% | -7.9% | -11.0% | +0.3% |
| Feb 26 | Oppenheimer | Maintains | Underperform → Underperform | — | $350.00 | $338.00 | -3.4% | -7.0% | -16.2% | -16.2% | -8.0% | -11.2% |
| Feb 18 | Citigroup | Upgrade | Neutral → Buy | — | $352.40 | $362.60 | +2.9% | +3.2% | +2.7% | +1.4% | +1.8% | -0.2% |
| Dec 16 | Stifel | Downgrade | Buy → Hold | — | $482.40 | $510.20 | +5.8% | -5.1% | -11.5% | -13.6% | -12.0% | -13.0% |
| Dec 16 | Oppenheimer | Maintains | Underperform → Underperform | — | $482.40 | $510.20 | +5.8% | -5.1% | -11.5% | -13.6% | -12.0% | -13.0% |
| Nov 18 | Citi | Downgrade | Buy → Neutral | — | $480.40 | $482.20 | +0.4% | -5.9% | -5.4% | -15.7% | -14.6% | -12.9% |
| Nov 18 | Citigroup | Downgrade | Buy → Neutral | — | $480.40 | $482.20 | +0.4% | -5.9% | -5.4% | -15.7% | -14.6% | -12.9% |
| Nov 2 | Citigroup | Downgrade | Buy → Neutral | — | $452.80 | $447.60 | -1.1% | +1.0% | +1.5% | +0.2% | -2.7% | -5.9% |
| Oct 17 | Citigroup | Maintains | Buy → Buy | — | $402.40 | $405.00 | +0.6% | +2.5% | -0.0% | -2.0% | -1.6% | +6.5% |
| Sep 25 | Jefferies | Maintains | Buy → Buy | — | $248.00 | $244.20 | -1.5% | +4.8% | +8.5% | +11.5% | +31.2% | +29.3% |
| Sep 25 | Citigroup | Maintains | Buy → Buy | — | $248.00 | $244.20 | -1.5% | +4.8% | +8.5% | +11.5% | +31.2% | +29.3% |
| Feb 18 | SunTrust Robinson Humphrey | Upgrade | Neutral → Buy | — | $23.60 | $27.40 | +16.1% | +11.0% | +22.9% | +12.7% | +20.3% | +16.9% |
| Nov 10 | Citigroup | Maintains | Neutral → Neutral | — | $18.00 | $17.40 | -3.3% | -7.8% | -6.7% | -1.1% | +5.6% | +5.6% |
| May 12 | Citigroup | Downgrade | Buy → Neutral | — | $30.20 | $29.60 | -2.0% | -1.3% | -0.7% | +0.7% | -9.3% | -9.3% |
| Feb 28 | Aegis Capital | Maintains | Hold → Hold | — | $35.60 | $35.00 | -1.7% | -2.2% | -2.8% | -2.2% | +1.1% | +2.8% |
| Jan 16 | MKM Partners | Downgrade | Buy → Neutral | — | $48.00 | $44.20 | -7.9% | -5.8% | -5.4% | -27.9% | -29.6% | -31.7% |
| Nov 8 | Citigroup | Upgrade | Neutral → Buy | — | $28.20 | $32.20 | +14.2% | +11.3% | +9.9% | +9.2% | +9.2% | +8.5% |
| Oct 30 | Aegis Capital | Maintains | Hold → Hold | — | $42.00 | $37.60 | -10.5% | -13.8% | -21.4% | -21.9% | -23.3% | -31.0% |
| Oct 30 | Leerink Swann | Downgrade | Outperform → Market Perform | — | $42.00 | $37.60 | -10.5% | -13.8% | -21.4% | -21.9% | -23.3% | -31.0% |
| Oct 18 | Citigroup | Downgrade | Buy → Neutral | — | $40.20 | $39.80 | -1.0% | +1.0% | +14.4% | +13.4% | +9.0% | +7.5% |
| Oct 17 | Canaccord Genuity | Downgrade | Buy → Hold | — | $103.40 | $41.40 | -60.0% | -61.1% | -60.7% | -55.5% | -55.9% | -57.6% |
| Oct 17 | H.C. Wainwright | Downgrade | Buy → Neutral | — | $103.40 | $41.40 | -60.0% | -61.1% | -60.7% | -55.5% | -55.9% | -57.6% |
| Oct 17 | JP Morgan | Downgrade | Overweight → Neutral | — | $103.40 | $41.40 | -60.0% | -61.1% | -60.7% | -55.5% | -55.9% | -57.6% |
| Oct 17 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $103.40 | $41.40 | -60.0% | -61.1% | -60.7% | -55.5% | -55.9% | -57.6% |
| Oct 16 | Aegis Capital | Downgrade | Buy → Hold | — | $103.40 | $103.40 | +0.0% | +0.0% | -61.1% | -60.7% | -55.5% | -55.9% |
| Oct 16 | SunTrust Robinson Humphrey | Downgrade | Buy → Neutral | — | $103.40 | $103.40 | +0.0% | +0.0% | -61.1% | -60.7% | -55.5% | -55.9% |
| Oct 16 | Leerink Swann | Maintains | Outperform → Outperform | — | $103.40 | $103.40 | +0.0% | +0.0% | -61.1% | -60.7% | -55.5% | -55.9% |
No insider trades available.
Data updated apr 26, 2026 9:34am
· Source: massive.com